Caxton Associates (New York)’s Novavax NVAX Stock Holding History

Caxton Associates (New York)’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,700	Closed	-$786K	–	551
2021 Q2	$786K	Buy	+3,700	New	+$678K	0.09%	102

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Caxton Associates (New York)'s NVAX Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Novavax (NVAX) in Q4 2024, closing a stake of 73,061 shares — an estimated $923K sold.

Caxton Associates (New York) first reported a position in NVAX in Q2 2020 and held it in 2 quarters. The position peaked at $923K in Q3 2024. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2024.

Caxton Associates (New York) reported no remaining Novavax position as of Q4 2024 after selling out during the quarter.
Caxton Associates (New York) sold 73,061 Novavax shares in Q4 2024, an estimated $923K.
Caxton Associates (New York) first reported a position in Novavax in Q2 2020 and held it in 2 quarters.
Caxton Associates (New York)'s Novavax position peaked at $923K in Q3 2024.
235 funds tracked by Wall St. Rank held Novavax as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.